Tradestie Institutional Equity Comparison Engine

CHAD vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Growth & Margin, Options & Structure while CHAD counters with relative strength in Momentum & Technical. Fundamentally, CHAD trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, CHAD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CHAD N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner ZBIO
Op Margin N/A vs -2747.5% ยท YoY N/A vs -100.0%
Momentum & Technical Winner CHAD
1Y +19.6% vs -21.7% ยท 52W Pos 100% vs 46%
Options & Structure Winner ZBIO
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (13th %ile IV)
CHAD US Equity
CHAD
Institutional Equity
$10.00
+0.21% 1D
Market Cap N/A
1M Return +7.07%
1Y Return +19.62%
Forward P/E N/M
Unified AI Score
53.8 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 43.0 Fund 54.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CHAD +19.62% ZBIO -21.68% Spread: +35.11 pp (CHAD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CHAD TTM Op. Margin: N/A ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHAD vs ZBIO. Trailing 12-month operating profitability (CHAD N/A vs ZBIO -2747.5%) and valuation multiples (CHAD N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CHAD (3) vs ZBIO (5)
Institutional Metric CHAD ZBIO Criterion Row Winner
Market Capitalization Scale N/A $1.9B Larger Scale ZBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A -100.0% Higher Growth ZBIO
Operating Margin (TTM) Profitability N/A -2747.5% Higher Margin ZBIO
Net Profit Margin Profitability N/A 0.0% Higher Margin ZBIO
Return on Equity (ROE) Capital Efficiency N/A -265.1% Higher ROE ZBIO
52-Week Range Position Momentum 100% ($7โ€“$10) 46% ($14โ€“$45) Stronger Trend CHAD
Beta / 30D Volatility Risk Regime 0.71ฮฒ ยท 11% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk CHAD
Unified Institutional Score Composite Signal 53.8 / 100 (HOLD) 47.8 / 100 (HOLD) Higher Composite CHAD

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CHAD vs ZBIO Buy Guide
CHAD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CHAD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CHAD nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.